Earnings Releases·Nov 12, 2026, 4:20 PM ET

Scribe Therapeutics — Third Quarter 2026 Earnings Summary

Q3 2026 net loss widened to $9.9 million ($0.68 per share) from $6.5 million in the prior quarter, driven by a $1.7 million increase in G&A expenses to $4.2 million, while R&D expenses declined to $8.3 million; total operating expenses for the nine-month period reached $38.5 million.
Cash and marketable securities surged to $174.2 million as of September 30, 2026, from $43.0 million in June, fueled by $140.2 million in net proceeds from the July 2026 IPO and concurrent private placement, resulting in positive stockholders' equity of $125.2 million compared to a $143.4 million deficit at year-end 2025.
The company expects its current cash position to fund operations and capital requirements through the first half of 2029, with initial Phase 1 clinical data for STX-1150 anticipated in the first half of 2027.
Strategic milestones include the completion of an upsized IPO trading under "SCTX" and an expanded collaboration with Sanofi granting access to both ELXR and XE technologies, alongside the presentation of new data demonstrating 10-fold reduced off-target effects for ELXR and >100-fold improved editing activity for XE.